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A little Cdc20 goes a long way
C
dc20 drives mitotic cells from 
metaphase into anaphase. Once 
metaphase chromosomes are 
aligned at the center of the mitotic spindle, 
Cdc20 activates the E3 ubiquitin ligase 
APC/C to trigger the degradation of cyclin 
B1 and securin, allowing sister chromatids 
to separate and move toward opposite poles 
(1). Cdc20 is so essential for mitotic progres-
sion that mouse embryos lacking the protein 
fail to pass the two-cell stage (2). “It’s easy 
to assume that you’ll be in big trouble if you 
don’t have near-normal levels of important 
proteins like Cdc20,” says Jan van Deursen, 
from the Mayo Clinic in Rochester, Minne-
sota. “But what happens if there’s enough 
Cdc20 for cells to get through mitosis but 
not enough for them to do it perfectly?” To 
fi  nd out, van Deursen and colleagues gen-
erated a series of mice expressing progres-
sively lower amounts of Cdc20 (3).
Malureanu et al. made animals express-
ing as little as 15–20% of normal Cdc20 
levels. Yet the mice seemed completely 
healthy. “We were very surprised, and also 
disappointed,” admits van Deursen. A closer 
look at isolated cells, however, revealed that 
aneuploidy—the presence of abnormal 
chromosome numbers—was increased in 
Cdc20 hypomorphic mice. “We looked at 
dividing cells and saw 
misaligned chromosomes, 
refl   ecting problems with 
kinetochore–microtubule 
attachments,” van Deursen 
explains. Cdc20 hasn’t been 
implicated in linking chro-
mosomes to the spindle be-
fore, though a small portion 
of the protein localizes to 
kinetochores in wild-type cells. This local-
ization was reduced in Cdc20-depleted 
cells, suggesting that Cdc20 could have a 
direct role in capturing microtubules to 
accurately segregate sister chromatids.
Alternatively, lower Cdc20 levels could 
indirectly affect chromosome alignment 
by reducing APC/C’s ability to target 
cyclin B1 and other mitotic proteins for 
destruction, resulting in the misregulation 
of kinetochore–microtubule attachments. 
Indeed, rather than gradually declining 
during metaphase, cyclin B1 levels in-
creased as Cdc20 hypomorphic cells went 
through mitosis. Malureanu et al. found 
that cyclin B1 mRNA was translated dur-
ing metaphase. Anaphase onset was delayed 
in Cdc20 hypomorphic cells, but blocking 
cyclin B1’s mitotic synthesis reduced the 
protein’s level and restored the timing of the 
metaphase-to-anaphase transition. Cyclin 
B1 was also synthesized in wild-type 
mitotic cells, though this is 
usually masked by the pro-
tein’s turnover at the hands 
of Cdc20 and the APC/C.
Why would metaphase 
cells simultaneously synthe-
size and degrade cyclin B1? 
Perhaps, says van Deursen, 
because the APC/C isn’t as 
selective as commonly 
thought. The complex appears to target 
cyclin A early in mitosis before turning its 
attention to cyclin B1, though how this 
order is maintained is unknown. Instead, 
van Deursen suggests, both cyclins may be 
targeted from the outset, but degraded 
cyclin B1 is initially replaced by the syn-
thesis of new protein during metaphase.
“Our fi  ndings open up a more dynamic 
view of cyclin B in mitosis,” van Deursen 
says. Rather than remaining stable until 
the last kinetochore is attached and meta-
phase is complete, cyclin B1 may be con-
tinuously degraded by Cdc20 and APC/C, 
which grow increasingly active as each 
chromosome correctly aligns. Cyclin B1 
synthesis would maintain the protein’s 
steady-state levels until all chromosomes 
were attached and ready for segregation.
“Our genetic approach gave us insights 
into Cdc20 and cyclin B1 function that 
weren’t apparent from other studies,” says 
van Deursen. “We could fi  nd subtle pheno-
types that you wouldn’t see in a mixed 
population of siRNA-treated cells.” Re-
maining questions include why, despite 
increased aneuploidy, Cdc20 mice are no 
more tumor prone than wild-type animals, 
even after treatment with carcinogens. 
One possibility is that the tumor-promoting 
effects of aneuploidy are balanced by an 
increased susceptibility to apoptosis when 
anaphase is delayed (4). Van Deursen also 
wants to look at Cdc20’s role in meiosis 
and to extend the hypomorphic approach 
to another APC/C activator called Cdh1.
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(L-R) Liviu Malureanu, Jan van Deursen, Karthik Jeganathan, and colleagues (not shown) uncover 
new details of Cdc20’s mitotic function by generating mice expressing greatly reduced amounts of 
the protein, which activates the APC/C ubiquitin ligase to drive mitotic cells into anaphase. The mice 
are overtly normal, but have higher levels of aneuploidy, probably due to defects in chromosome 
alignment (far right), indicating an additional function for Cdc20 in kinetochore–microtubule 
attachment. The approach also revealed that the mitotic regulator cyclin B1 is actively synthesized 
during metaphase, at the same time that it is targeted for destruction by Cdc20 and the APC/C.
“Our findings 
open up a more 
dynamic view 
of cyclin B 
in mitosis.”
Hypomorphic mice reveal new details of Cdc20 and cyclin B1’s mitotic activities.
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